Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of VX-770 in Cystic Fibrosis
NCT01117012Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Non-Serious Adverse Events and Serious Adverse Events. Started Jul 2010; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01117012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117012.